(firstQuint)Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis.

 Icotinib Hydrochloride is an oral, small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which has been approved for treating advanced non-small cell lung cancer (NSCLC) in China.

 Over-expressions of EGFR and its downstream signaling proteins are implicated in the pathogenesis of psoriasis and TKIs have been considered as potential antipsoriatic agents.

 Icotinib hydrochloride is being developed as a cream for the treatment of mild to moderate psoriasis.

 This is a multicenter , randomized, doubleblind, four-arm parallel-group, placebo-controlled phase II study to assess the efficacy and safety of icotinib hydrochloride cream (1.

0%, 2.

0%, 4.

0%) in patients with mild to moderate psoriasis.

 Approximately 260 subjects will be enrolled.

.

 Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis@highlight

This is a phase II study to evaluate the efficacy and safety of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.

